RecruitingPhase 3NCT03925662

Mebendazole as Adjuvant Treatment for Colon Cancer

Clinical Study Evaluating Mebendazole as Adjuvant Therapy in Patients With Colorectal Cancer


Sponsor

Sherief Abd-Elsalam

Enrollment

40 participants

Start Date

Apr 1, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

mebendazole treating colon cancer


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether mebendazole — an inexpensive antiparasitic medication widely used to treat intestinal worms — can also help slow the growth of stage 4 colorectal cancer when added to standard treatment. **You may be eligible if...** - You have stage 4 colorectal cancer (cancer that has spread to other organs) - You are able to provide informed consent **You may NOT be eligible if...** - You have agranulocytosis (a severe condition where white blood cell counts are dangerously low) - You are pregnant - You have a known allergy to mebendazole Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFolfox with avastin

Folfox with avastin only

DRUGMebendazole

Folfox with avastin with mebendazole


Locations(1)

Sherief Abd-Elsalam

Cairo, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03925662


Related Trials